2024
Early Release - Public Health Impact of Paxlovid as Treatment for COVID-19, United States - Volume 30, Number 2—February 2024 - Emerging Infectious Diseases journal - CDC
Bai Y, Du Z, Wang L, Lau E, Fung I, Holme P, Cowling B, Galvani A, Krug R, Meyers L. Early Release - Public Health Impact of Paxlovid as Treatment for COVID-19, United States - Volume 30, Number 2—February 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: 262-269. PMID: 38181800, PMCID: PMC10826746, DOI: 10.3201/eid3002.230835.Peer-Reviewed Original Research
2013
Cost-effectiveness of a community-based intervention for reducing the transmission of Schistosoma haematobium and HIV in Africa
Mbah M, Kjetland EF, Atkins KE, Poolman EM, Orenstein EW, Meyers LA, Townsend JP, Galvani AP. Cost-effectiveness of a community-based intervention for reducing the transmission of Schistosoma haematobium and HIV in Africa. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 7952-7957. PMID: 23589884, PMCID: PMC3651507, DOI: 10.1073/pnas.1221396110.Peer-Reviewed Original ResearchConceptsCommunity-based interventionsHIV infectionHIV transmissionSchistosoma haematobiumFemale genital schistosomiasisAdministration of praziquantelSaharan AfricaRural ZimbabweS. haematobium transmissionGenital schistosomiasisGenital infectionHealth payersSchool-aged childrenIntervention periodEpidemiological dataEpidemiological studiesS. haematobiumSchistosomiasis prevalenceHealth educationInfectionSchistosomiasisYoung womenHaematobiumInterventionHIV
2010
Adherence to cervical screening in the era of human papillomavirus vaccination: how low is too low?
Bauch CT, Li M, Chapman G, Galvani AP. Adherence to cervical screening in the era of human papillomavirus vaccination: how low is too low? The Lancet Infectious Diseases 2010, 10: 133-137. PMID: 20113982, DOI: 10.1016/s1473-3099(10)70004-9.Peer-Reviewed Original ResearchConceptsCervical cancerVaccinated womenVaccine coverageEffective cervical screening programmesHuman papillomavirus vaccinationCervical screening programmeHigh-risk typesIntroduction of vaccinesPapillomavirus vaccinationOncogenic typesCervical screeningOpportunistic screeningScreening programPrevents infectionCancerVaccineIncidenceContinued screeningWomenVaccinationScreeningPopulationDisease incidenceInfection